Thermo Fisher Scientific reported better-than-expected Q2 2025 results, with revenues up 3% year-over-year to $10.86 billion and adjusted EPS of $5.36 surpassing consensus. Growth was notable in life sciences solutions and laboratory products segments, despite a slight decline in analytical instruments. The company raised full-year guidance for revenues and earnings, citing $300 million in cost savings actions and improved tariff outlook. CFO Stephen Williamson announced retirement effective March 2026, with Jim Meyer named successor. The stock surged approximately 11% on the news.